Oncology Clinical Trial
Official title:
Characteristics of the Intestinal Microbiota in Patients With Cancer (Catalogue-Onco)
In order to understand how the intestinal microbiota plays a role in the effectiveness of an
anti-cancer treatment by an immune control point inhibitor, this study aims to constitute a
catalog of microbial genes of a patient with cancer. This catalog will help to characterize
the intestinal microbiota of cancer patients and to be able to use this catalog as a
reference tool for screening the microbiota of patients treated with immune control point
inhibitors. To produce this catalog, five types of cancer were selected: non-small cell lung
cancer, colorectal cancer, hepatocellular carcinoma, breast cancer and prostate cancer.
The metagenomic analysis of a group of five different types of cancers introduces a lot of
heterogeneity which is favorable to the richness of a catalog. For non-small cell lung cancer
treated with immune control point inhibitors, two stool collections will be performed per
patient (one stool collection before setting up an immune control point inhibitor and one
collection after one month of being inhibited Of immune control point) to assess the impact
of the immune control point inhibitor on the microbiota (pilot study). For this study, two
stool collection tubes containing different preservative solutions will be used (one RNAlater
tube and one DMSO-EDTA tube for Dimethylsulfoxide-Ethylene diamine tetraacetic acid).
In parallel, we will also collect samples of serum and plasma to evaluate, in a second step,
protein markers in circulating blood.
Primary objective: Develop a catalog of microbial genes dedicated to oncology (Onco catalog) by sequencing stool specimens from patients with cancer. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01439152 -
Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Active, not recruiting |
NCT06015009 -
Symptom Management App for Children at the Early Stage of Cancer Survivorship and Their Caregivers
|
N/A | |
Active, not recruiting |
NCT03298100 -
Risk Scoring Model for Endometrial Cancer
|
||
Recruiting |
NCT05055609 -
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT04324320 -
Psychological Distress in Outpatient Oncological Rehabilitation
|
||
Completed |
NCT00588289 -
Long Term Follow-Up of Patients on Children's Cancer Group Protocols- (CCG-LTF1) FOLLOW-UP DATA
|
N/A | |
Recruiting |
NCT06222801 -
The 1st Tumor CytokinoTherapy Database (TCTD-1)
|
||
Recruiting |
NCT03831633 -
Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients
|
Phase 4 | |
Completed |
NCT04914702 -
Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
|
||
Recruiting |
NCT05198570 -
Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients
|
||
Recruiting |
NCT05712174 -
A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT03832062 -
Value of Analysing Under-utilised Leftover Tissue (VauLT)
|
||
Completed |
NCT03988777 -
Magnetic Seed Localisation for Nonpalpable Breast Lesions
|
||
Recruiting |
NCT06031233 -
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
|
Phase 4 | |
Enrolling by invitation |
NCT04019119 -
Digital Intervention for the Modification of Lifestyles (iGame)
|
N/A | |
Not yet recruiting |
NCT05926362 -
Capillary-Venous Paired Data Collection
|
||
Recruiting |
NCT05510856 -
Comparative Clinical Study Evaluating the Possible Efficacy of Duloxetine, Gabapentin and Lacosamide on Oxaliplatin-Induced Peripheral Neuropathy in Cancer Patients
|
Phase 4 | |
Recruiting |
NCT05686213 -
ExeNTrO: Exercise During Neoadjuvant Chemoradiation Treatment to Improve Rectal and Esophageal Cancer Outcome - Pilot Trial
|
Phase 2 | |
Completed |
NCT04180306 -
PEWS Implementation in an LMIC Setting
|
N/A |